Therapeutic Senolysis of Axitinib-Induced Senescent Human Lung Cancer Cells.
Hitoshi KotaniWei HanYuichi IidaRyosuke TaninoKazuaki KatakawaTamio OkimotoYukari TsubataTakeshi IsobeMamoru HaradaPublished in: Cancers (2024)
Axitinib, but not lenvatinib, induced cellular senescence (increased cell size and enhanced expression of β-galactosidase) in all adenocarcinoma cell lines. Axitinib-induced senescence was unrelated to the expression of VEGFRs on cancer cells. ROS were involved in axitinib-induced senescence. Axitinib-induced senescent lung adenocarcinoma A549 cells were drastically lysed by ABT-263. In A549-xenografted mice, combination therapy with axitinib and ABT-263 significantly suppressed tumor growth with the induction of apoptotic cancer cells.
Keyphrases
- high glucose
- endothelial cells
- diabetic rats
- combination therapy
- dna damage
- squamous cell carcinoma
- oxidative stress
- cell death
- type diabetes
- induced apoptosis
- single cell
- radiation therapy
- binding protein
- insulin resistance
- cell therapy
- cell proliferation
- signaling pathway
- reactive oxygen species
- locally advanced
- high fat diet induced
- pi k akt
- rectal cancer